全文获取类型
收费全文 | 686篇 |
免费 | 50篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 32篇 |
妇产科学 | 9篇 |
基础医学 | 77篇 |
口腔科学 | 9篇 |
临床医学 | 50篇 |
内科学 | 184篇 |
皮肤病学 | 19篇 |
神经病学 | 36篇 |
特种医学 | 138篇 |
外科学 | 62篇 |
综合类 | 34篇 |
预防医学 | 28篇 |
眼科学 | 6篇 |
药学 | 37篇 |
肿瘤学 | 27篇 |
出版年
2021年 | 6篇 |
2020年 | 4篇 |
2019年 | 4篇 |
2018年 | 8篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 15篇 |
2014年 | 8篇 |
2013年 | 14篇 |
2012年 | 8篇 |
2011年 | 22篇 |
2010年 | 25篇 |
2009年 | 33篇 |
2008年 | 25篇 |
2007年 | 34篇 |
2006年 | 29篇 |
2005年 | 35篇 |
2004年 | 35篇 |
2003年 | 16篇 |
2002年 | 25篇 |
2001年 | 28篇 |
2000年 | 16篇 |
1999年 | 9篇 |
1998年 | 23篇 |
1997年 | 39篇 |
1996年 | 22篇 |
1995年 | 24篇 |
1994年 | 17篇 |
1993年 | 7篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 11篇 |
1989年 | 22篇 |
1988年 | 12篇 |
1987年 | 18篇 |
1986年 | 11篇 |
1985年 | 13篇 |
1984年 | 8篇 |
1983年 | 13篇 |
1982年 | 9篇 |
1981年 | 9篇 |
1980年 | 15篇 |
1979年 | 6篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1976年 | 9篇 |
1975年 | 6篇 |
1972年 | 3篇 |
1969年 | 2篇 |
1965年 | 2篇 |
排序方式: 共有749条查询结果,搜索用时 15 毫秒
91.
Demonstration of reversible priming of human neutrophils using platelet- activating factor 总被引:3,自引:1,他引:3
Exposure of neutrophils to agents such as lipopolysaccharide, tumor necrosis factor-alpha (TNF-alpha), and the granulocyte-macrophage colony-stimulating factor causes a major upregulation of subsequent agonist-induced NADPH oxidase activation. This priming effect is a prerequisite for neutrophil-mediated tissue damage and has been widely considered to be an irreversible process. We have investigated the potential for neutrophils to recover from a priming stimulus by studying the effects of platelet-activating factor (PAF). PAF did not stimulate respiratory burst activity directly, but caused a rapid (maximal at 10 minutes) and concentration-dependent (EC50 50.2 nmol/L) increase in N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated superoxide anion release. At time-points > 10 minutes, this priming effect spontaneously declined, with return to basal levels of fMLP- stimulated superoxide anion generation by 120 minutes. An identical priming time-course was observed with N-methyl carbamyl PAF, a nonmetabolizable analogue of PAF, indicating that the transient nature of PAF-induced priming was not secondary to PAF metabolism. Two structurally diverse PAF receptor antagonists (UK-74,505 and WEB 2086), added 10 minutes after PAF addition, increased the rate of decay of the priming effect. In contrast, TNF-alpha-induced priming, which was of a similar magnitude to that observed for PAF, was slower to evolve (maximal at 30 minutes) and remained constant for at least 120 minutes. The reversible nature of PAF-induced priming was confirmed by demonstrating that PAF-, but not TNF-alpha-, induced cell polarization (shape change) and CD11b-dependent neutrophil binding of albumin-coated latex beads was also transient, with return to basal, unstimulated levels by 120 minutes. Furthermore, cells that had spontaneously deprimed following PAF exposure retained their capacity to be fully reprimed by a subsequent addition of either PAF or TNF-alpha. These data imply that neutrophil priming is not an irreversible event: the demonstration of a cycle of complete priming, depriming, and repriming offers the potential for functional recycling of neutrophils at sites of inflammation. 相似文献
92.
93.
Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation 总被引:6,自引:0,他引:6
During the course of differentiation of early human myeloid cells toward monocytes and granulocytes, cell surface expression of the cell adhesion molecule, CD11b/CD18 (Mo1) increases dramatically and expression of myeloperoxidase (MPO), a bacteriocidal enzyme, decreases markedly. Using the inducible promyelocytic cell line HL-60 as a model, we studied the mRNA expression of these genes. Differentiation of these cells along both a monocytic and a granulocytic pathway demonstrated that the mRNA levels of the two subunits of CD11b/CD18 increased in a pattern temporally and quantitatively similar to the increase in cell surface expression of this heterodimer. In contrast, the expression of MPO mRNA decreased in a temporal and quantitative pattern similar to the known decrease in MPO protein during differentiation, suggesting that regulation of these myeloid-specific proteins may occur at the level of mRNA expression. These findings have important implications with regard to the nature of the block in differentiation in acute nonlymphocytic leukemia and the regulation of myeloid gene expression. 相似文献
94.
The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation 总被引:11,自引:14,他引:11
Petersdorf EW; Longton GM; Anasetti C; Martin PJ; Mickelson EM; Smith AG; Hansen JA 《Blood》1995,86(4):1606-1613
Despite matching for serologically defined HLA-A, B, DR antigens, acute graft-versus-host disease (GVHD) is a major complication contributing to increased morbidity and mortality in patients who undergo marrow transplantation from unrelated donors. The extent to which unrecognized mismatching for alleles that encode DR1-DR18 contribute to the increased risk of acute GVHD and overall survival is unknown. We analyzed 364 patients and their HLA-A, B, DR serologically matched donors to determine whether molecular typing of DRB1 alleles can allow more accurate donor/recipient matching and thereby improve clinical outcome after marrow transplantation. DRB1 alleles were typed by sequence-specific oligonucleotide probe hybridization methods. Selected alleles were confirmed by DNA sequencing. Of the 364 pairs, 305 were matched and 59 were mismatched for DRB1. The probability of moderate to severe acute GVHD was .48 for the matched and .70 for the mismatched patients. Compared with mismatched patients, the estimated relative risk (RR) of GVHD for matched patients was .58 (95% confidence interval [CI], .40 to .85). DRB1 matching decreased the risk of transplant- related mortality (RR, .66; 95% CI, .44 to .97) and was associated with decreased overall mortality (RR, .71; 95% CI, .51 to 1.0). Therefore, matching DRB1 alleles of the donor and recipient decreases the risk of acute GVHD and improves survival after unrelated marrow transplantation. These results indicate that prospective matching of patients and donors for DRB1 alleles is warranted. 相似文献
95.
96.
Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity 总被引:1,自引:0,他引:1
MacDonald AG; Birkinshaw G; Durham B; Bucknall RC; Fraser WD 《Rheumatology (Oxford, England)》1997,36(1):50-53
To investigate bone turnover in patients with seronegative
spondylarthropathy, a bone formation marker, type 1 procollagen carboxy-
terminal propeptide (P1CP), and resorption markers, the pyridinium
cross-links of collagen [urinary free (f) PYR and DPYR], were measured. The
median f-PYR, f-DPYR and P1CP (+/-interquartile range) were 15.8 (6.00)
nmol/mmol creatinine, 3.8 (2.2) nmol/mmol creatinine and 101.5 (38)
micrograms/1, respectively. There was a positive correlation between
resorption markers and acute-phase reactants such as C-reactive protein (r
= 0.42 for PYR, r = 0.42 for DPYR, P < 0.05), and a negative correlation
observed between P1CP and the erythrocyte sedimentation rate (r = -0.64, P
< 0.05). In the subgroup of patients with an elevated CRP concentration,
the concentration of PYR and DPYR was significantly increased (f-PYR 25.7
vs 15.8 and f-DPYR 6.6 vs 3.8, P < 0.01 for f-PYR, P < 0.05 for
f-DPYR). This study suggests than an elevation in acute-phase response in
patients with seronegative spondylarthropathy is associated with increased
concentration of bone resorption markers with a tendency for reduction in
bone formation markers. This may represent uncoupling of bone formation and
resorption, leading to bone loss in such patients.
相似文献
97.
To elucidate the usefulness of beta-thromboglobulin (beta TG) in the differentiation of the mechanism of thrombocytopenia, plasma beta TG concentration was measured in one patient with amegakaryocytic thrombocytopenia, four patients with autoimmune thrombocytopenia (ATP), two patients with thrombotic thrombocytopenia (TTP), and one patient with thrombocytopenia secondary to disseminated intravascular coagulation (DIC). Plasma beta TG was not measurable in amegakaryocytic thrombocytopenia, was normal in ATP, and was increased in TTP and DIC. These data indicate that in thrombocytopenic patients, increased plasma beta TG concentration may result from intravascular platelet consumption with release of platelet constituents in contrast to extravascular platelet destruction by the macrophage-monocyte system. 相似文献
98.
Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial 总被引:3,自引:0,他引:3
R D Hull J Hirsh C J Carter R M Jay P A Ockelford H R Buller A G Turpie P Powers D Kinch P E Dodd 《Annals of internal medicine》1985,102(1):21-28
Impedance plethysmography is an accurate noninvasive method to test for proximal vein thrombosis, but it is insensitive to calf-vein thrombi. We randomly assigned patients on referral with clinically suspected deep-vein thrombosis and normal impedance plethysmographic findings to either serial impedance plethysmography alone or combined impedance plethysmography and leg scanning (which has been shown to be essentially as sensitive as venography) and compared the long-term outcomes. During the initial surveillance, deep-vein thrombosis was detected in 6 of 311 patients (1.9%) tested by serial impedance plethysmography alone and in 30 of 323 patients (9.3%) (most with calf-vein thrombi) tested by the combined approach (p less than 0.001). During long-term follow-up, no patient died from pulmonary embolism; but 6 patients (1.9%; 95% confidence limits, 0.7% to 4.2%) tested by serial impedance plethysmography developed deep-vein thrombosis compared with 7 patients (2.2%; 95% confidence limits, 0.9% to 4.4%) tested by the combined approach. Serial impedance plethysmography used alone is an effective strategy to evaluate such symptomatic patients. 相似文献
99.
100.
New oral anticoagulants in atrial fibrillation. 总被引:2,自引:0,他引:2
Alexander G G Turpie 《European heart journal》2008,29(2):155-165
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the only approved antithrombotic therapies for stroke prevention in patients with AF. Although effective, VKAs have unpredictable pharmacological effects, requiring regular coagulation monitoring and dose adjustment to maintain effects within the therapeutic range. The clinical development pathway for novel anticoagulants often involves evaluation of efficacy and safety in a short-term indication, such as the prevention of venous thrombo-embolism (VTE), followed by longer-term VTE treatment studies, and finally chronic indications, including stroke prevention studies in patients with AF. The coagulation pathway provides many targets for novel anticoagulants, including Factor Xa (FXa) and Factor IIa (thrombin). Numerous oral, direct FXa inhibitors are in various stages of clinical development, including rivaroxaban, LY517717, YM150, DU-176b, apixaban, and betrixaban, and are anticipated to overcome the limitations of VKAs. Dabigatran is the only oral direct thrombin inhibitor in late-stage development. Studies of these agents for stroke prevention in patients with AF are planned or ongoing. If approved, they may represent the next generation of anticoagulants, by providing new therapeutic options for stroke prevention in patients with AF. 相似文献